Edition:
India

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

6,241.00GBp
15 Feb 2019
Change (% chg)

92.00 (+1.50%)
Prev Close
6,149.00
Open
6,149.00
Day's High
6,251.00
Day's Low
6,123.00
Volume
2,672,278
Avg. Vol
2,100,019
52-wk High
6,432.48
52-wk Low
4,699.00

Select another date:

Thu, Feb 14 2019

CORRECTED-AstraZeneca, Micro Focus lift FTSE 100; midcap ConvaTec sinks

Feb 14 Britain's main index on Thursday held onto a more than four-month high hit in the last session, aided by earnings-driven gains in drugmaker AstraZeneca and software firm Micro Focus and boosted by forecast-beating trade data from China.

New cancer drugs help upbeat AstraZeneca beat forecasts

AstraZeneca forecast a second straight year of sales growth on Thursday, driven by cancer medicines and other new drugs as the British drugmaker recovers from losing major patents.

AstraZeneca product sales top forecasts with 8 pct rise

Feb 14 British drugmaker AstraZeneca Plc reported an 8 percent rise in product sales for the fourth quarter on Thursday, beating analysts' expectations on the back of strong demand for newer drugs including cancer medicines.

AstraZeneca's infant respiratory drug prioritised in Europe, U.S.

LONDON Britain's AstraZeneca said a potential medicine to prevent respiratory syncytial virus (RSV) in babies and infants had been granted special status by U.S. and European regulators, designed to speed up the development of novel and better drugs.

AstraZeneca's infant respiratory drug prioritised in Europe, U.S.

LONDON, Feb 5 Britain's AstraZeneca said a potential medicine to prevent respiratory syncytial virus (RSV) in babies and infants had been granted special status by U.S. and European regulators, designed to speed up the development of novel and better drugs.

AstraZeneca picks Baselga to lead oncology R&D in growth plan

AstraZeneca said on Monday it had hired José Baselga to head research and development in oncology, an area where the British pharmaceuticals firm is seeking to grow its business.

UPDATE 2-AstraZeneca picks Baselga to lead oncology R&D in growth plan

* Creates R&D units for biopharmaceuticals and oncology (Adds comments from José Baselga, updates shares)

AstraZeneca picks Baselga to lead oncology R&D in growth plan

AstraZeneca said on Monday it had hired José Baselga to head research and development in oncology, an area where the British drugs firm is seeking to grow its business.

AstraZeneca appoints Baselga to head R&D for oncology

Jan 7 AstraZeneca Plc has appointed José Baselga to head research and development for oncology as it looks to align the unit with its commercial operations to drive growth.

AstraZeneca's ovarian cancer and anemia treatments meet goals in late-stage studies

British drugmaker AstraZeneca on Thursday said its ovarian cancer and anemia treatments met their goals in three separate late stage trials.

Select another date: